WO2014033170A1 - Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b - Google Patents
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b Download PDFInfo
- Publication number
- WO2014033170A1 WO2014033170A1 PCT/EP2013/067821 EP2013067821W WO2014033170A1 WO 2014033170 A1 WO2014033170 A1 WO 2014033170A1 EP 2013067821 W EP2013067821 W EP 2013067821W WO 2014033170 A1 WO2014033170 A1 WO 2014033170A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- mmol
- alkyl
- independently selected
- group
- Prior art date
Links
- 0 Cc1cc(NC(c2cc(S(N*(CCOC3)C3C=S)(=O)=O)ccc2)=O)ccc1OC Chemical compound Cc1cc(NC(c2cc(S(N*(CCOC3)C3C=S)(=O)=O)ccc2)=O)ccc1OC 0.000 description 2
- BDHMQGDCUCSDHX-UHFFFAOYSA-N C1NCC11COCC1 Chemical compound C1NCC11COCC1 BDHMQGDCUCSDHX-UHFFFAOYSA-N 0.000 description 1
- XSGQUACHCOGIAA-UHFFFAOYSA-N CC(CCN1CCOCC1)NS(c1cccc(C(Nc(cc2C)ccc2F)=O)c1)(=O)=O Chemical compound CC(CCN1CCOCC1)NS(c1cccc(C(Nc(cc2C)ccc2F)=O)c1)(=O)=O XSGQUACHCOGIAA-UHFFFAOYSA-N 0.000 description 1
- HXUUOIVPHYIXCI-UHFFFAOYSA-N CC(Cc1ccncc1)NS(c1cc(C(Nc(cc2)cc(C)c2F)=O)ccc1)(=O)=O Chemical compound CC(Cc1ccncc1)NS(c1cc(C(Nc(cc2)cc(C)c2F)=O)ccc1)(=O)=O HXUUOIVPHYIXCI-UHFFFAOYSA-N 0.000 description 1
- WQZIZUJSINLSGR-UHFFFAOYSA-N CC(c1ccccn1)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O Chemical compound CC(c1ccccn1)NS(c1cc(C(Nc(cc2C)ccc2F)=O)ccc1)(=O)=O WQZIZUJSINLSGR-UHFFFAOYSA-N 0.000 description 1
- XVXKDNBLKASYKQ-UHFFFAOYSA-N CC1(COC1)NS(c(c(Cl)c1C(Nc(cc2F)ccc2F)=O)ccc1F)(=O)=O Chemical compound CC1(COC1)NS(c(c(Cl)c1C(Nc(cc2F)ccc2F)=O)ccc1F)(=O)=O XVXKDNBLKASYKQ-UHFFFAOYSA-N 0.000 description 1
- IIOFRMHJROXNHR-UHFFFAOYSA-N CC1(COC1)NS(c(ccc(Br)c1C(Nc(cc2)cc(C#N)c2F)=O)c1F)(=O)=O Chemical compound CC1(COC1)NS(c(ccc(Br)c1C(Nc(cc2)cc(C#N)c2F)=O)c1F)(=O)=O IIOFRMHJROXNHR-UHFFFAOYSA-N 0.000 description 1
- NCAUMHFDWNRFNY-UHFFFAOYSA-N CCC1(COC1)NS(c1cccc(C(Nc(cc2)ccc2F)=O)c1)(=O)=O Chemical compound CCC1(COC1)NS(c1cccc(C(Nc(cc2)ccc2F)=O)c1)(=O)=O NCAUMHFDWNRFNY-UHFFFAOYSA-N 0.000 description 1
- OSFBCLXRULKHFO-INIZCTEOSA-N C[C@@H](C1CCCCC1)SNS(c1cccc(C(Nc(cc2)cc(C)c2F)=O)c1)(=O)=O Chemical compound C[C@@H](C1CCCCC1)SNS(c1cccc(C(Nc(cc2)cc(C)c2F)=O)c1)(=O)=O OSFBCLXRULKHFO-INIZCTEOSA-N 0.000 description 1
- BFJKCBOMFLCCRV-FQEVSTJZSA-N C[C@](CCOC1)(C1=S)NS(c1cccc(C(Nc(c(F)c2C)ccc2F)=O)c1)(=O)=O Chemical compound C[C@](CCOC1)(C1=S)NS(c1cccc(C(Nc(c(F)c2C)ccc2F)=O)c1)(=O)=O BFJKCBOMFLCCRV-FQEVSTJZSA-N 0.000 description 1
- YQCGFSABTFPKRQ-UHFFFAOYSA-N Cc(c(C(Nc(cc1)cc(C(F)F)c1F)=O)c1)ccc1S1(=O)=[O]C2(COC2)N1 Chemical compound Cc(c(C(Nc(cc1)cc(C(F)F)c1F)=O)c1)ccc1S1(=O)=[O]C2(COC2)N1 YQCGFSABTFPKRQ-UHFFFAOYSA-N 0.000 description 1
- RXNLRODYLMRKKW-UHFFFAOYSA-N Cc(cc(cc1)NC(c2cccc(S(NC3CCCC3)(=O)=O)c2)=O)c1F Chemical compound Cc(cc(cc1)NC(c2cccc(S(NC3CCCC3)(=O)=O)c2)=O)c1F RXNLRODYLMRKKW-UHFFFAOYSA-N 0.000 description 1
- JWSKSEQKWXBGGY-UHFFFAOYSA-N Cc1cc(NC(c2cc(S(NC(CC3)CCC3(F)F)(=O)=O)ccc2)=O)ccc1F Chemical compound Cc1cc(NC(c2cc(S(NC(CC3)CCC3(F)F)(=O)=O)ccc2)=O)ccc1F JWSKSEQKWXBGGY-UHFFFAOYSA-N 0.000 description 1
- MSQHXDIDDRMOPI-JCNLHEQBSA-N Cc1cc(NC(c2cc(S(N[C@H](CC3)CC[C@@H]3O)(=O)=O)ccc2)=O)ccc1F Chemical compound Cc1cc(NC(c2cc(S(N[C@H](CC3)CC[C@@H]3O)(=O)=O)ccc2)=O)ccc1F MSQHXDIDDRMOPI-JCNLHEQBSA-N 0.000 description 1
- TWIDJDHALUOUHE-UHFFFAOYSA-N O=C(c(cc(cc1)S(NC2CCCCC2)(=O)=O)c1F)Nc1cc(Cl)ccc1 Chemical compound O=C(c(cc(cc1)S(NC2CCCCC2)(=O)=O)c1F)Nc1cc(Cl)ccc1 TWIDJDHALUOUHE-UHFFFAOYSA-N 0.000 description 1
- HSZADYWMVDKBJH-UHFFFAOYSA-N O=C(c(cccc1S2(=O)=[O]COCN2)c1F)Nc(cc1C(F)(F)F)ccc1F Chemical compound O=C(c(cccc1S2(=O)=[O]COCN2)c1F)Nc(cc1C(F)(F)F)ccc1F HSZADYWMVDKBJH-UHFFFAOYSA-N 0.000 description 1
- BEPZMRKZNDOERS-UHFFFAOYSA-N O=C(c1cccc(S(NC2COC2)(=O)=O)c1)Nc(cc1)ccc1F Chemical compound O=C(c1cccc(S(NC2COC2)(=O)=O)c1)Nc(cc1)ccc1F BEPZMRKZNDOERS-UHFFFAOYSA-N 0.000 description 1
- MXOCYUWVOWFDPP-UHFFFAOYSA-N OCc1cc(NC(c2cc(S3(=O)=[O]C4(COC4)N3)ccc2)=O)ccc1F Chemical compound OCc1cc(NC(c2cc(S3(=O)=[O]C4(COC4)N3)ccc2)=O)ccc1F MXOCYUWVOWFDPP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/46—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom
- C07D333/48—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings substituted on the ring sulfur atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the Hepatitis B virus is an enveloped, partially double- stranded DNA (dsDNA) virus of the Hepadnavirus family (Hepadnaviridae). Its genome contains 4 overlapping reading frames: the precore/core gene; the polymerase gene; the L, M, and S genes, which encode for the 3 envelope proteins; and the X gene.
- the partially double-stranded DNA genome (the relaxed circular DNA; rcDNA) is converted to a covalently closed circular DNA (cccDNA) in the nucleus of the host cell and the viral mRNAs are transcribed.
- the pregenomic RNA (pgRNA), which also codes for core protein and Pol, serves as the template for reverse transcription, which regenerates the partially dsDNA genome (rcDNA) in the nucleocapsid.
- HBV has caused epidemics in parts of Asia and Africa, and it is endemic in China. HBV has infected approximately 2 billion people worldwide of which approximately 350 million people have developed chronic infections. The virus causes the disease hepatitis B and chronic infection is correlated with a strongly increased risk for the development cirrhosis and hepatocellular carcinoma.
- Transmission of hepatitis B virus results from exposure to infectious blood or body fluids, while viral DNA has been detected in the saliva, tears, and urine of chronic carriers with high titer DNA in serum.
- heteroaryldihydropyrimidines were identified as a class of HBV inhibitors in tissue culture and animal models (Weber et al., Antiviral Res. 54: 69-78).
- WO2013/006394 published on January 10, 2013, and WO2013/096744, published on June 27, 2013 relate to subclasses of Sulphamoyl-arylamides active against HBV.
- HBV direct antivirals may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability and difficulty of synthesis.
- HBV inhibitors may overcome at least one of these disadvantages or that have additional advantages such as increased potency or an increased safety window.
- the present invention relates to compounds of Formula (I)
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- Each R4 is independently selected from hydrogen, halogen, Ci-C 4 alkyloxy, Ci-C 4 alkyl, Ci-C 4 alkenyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N, such Ci-C 4 alkyl optionally substituted with OH;
- R 5 represents Ci-C 6 alkyl, CFH 2 , CF 2 H, CF 3i phenyl, pyridyl or a 3-7 membered
- saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 4 alkyloxy,
- Ci-C 4 alkyloxycarbonyl, oxo, C( 0)-Ci-C 3 alkyl, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ;
- the invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (I), and a pharmaceutically acceptable carrier.
- the invention also relates to the compounds of Formula (I) for use as a medicament, preferably for use in the prevention or treatment of an HBV infection in a mammal.
- the invention relates to a combination of a compound of Formula (I), and another HBV inhibitor.
- Ci_ 3 alkyl or "Ci-C 3 alkyl” as a group or part of a group refers to a hydrocarbyl radical of Formula C n H 2n+ i wherein n is a number ranging from 1 to 3. In case Ci_ 3 alkyl is coupled to a further radical, it refers to a Formula C n H 2n ..
- Ci_ 3 alkyl groups comprise from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms.
- Ci_ 3 alkyl includes all linear, or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, and /-propyl.
- Ci_ 4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the group defined for Ci_ 3 alkyl and butyl and the like.
- Ci_ 6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as the groups defined for Ci_ 4 alkyl and pentyl, hexyl, 2-methylbutyl and the like.
- Ci_ 4 alkenyl as a group or part of a group defines straight or branched chain
- hydrocarbon radicals having from 1 to 4 carbon atoms with at least one double bond at any possible position.
- alkenyls are ethenyl, propenyl, 1-butenyl, 2-butenyl.
- Ci_ 6 alkenyl as a group or part of a group defines straight or branched chain hydrocarbon radicals having from 1 to 6 carbon atoms with at least one double bond.
- Ci_3alkyloxy refers to a radical having the Formula— OR c wherein R c is Ci_ 3 alkyl.
- suitable Ci_ 3 alkyloxy include methyloxy (also methoxy), ethyloxy (also ethoxy), propyloxy and
- 3-7 membered saturated ring means saturated cyclic hydrocarbon with 3, 4, 5, 6 or 7 carbon atoms and is generic to cyclopropyl, eye lo butyl, cyclopentyl, cyclohexyl and cycloheptyl.
- Such saturated ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- heteroatoms such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- Examples include oxetane, azetidine, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl and pyrrolidinyl.
- Preferred are saturated cyclic hydrocarbon with 3 or 4 carbon atoms and 1 oxygen atom. Examples include oxetane and tetrahydrofuranyl.
- the term monocyclic 5 to 6 membered aromatic ring (“aryl”) means an aromatic cyclic hydrocarbon with 5 or 6 carbon atoms.
- a preferred example of an aryl group is phenyl.
- Such saturated ring optionally contains one or more heteroatoms each independently selected from the group consisting of O, S and N("heteroaryl")
- a heteroaryl group need only have some degree of aromatic character.
- heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidyl, pyrazyl, triazinyl, pyrrolyl, pyrazolyl, imidazolyl, (1 ,2,3,)- and (l ,2,4)-triazolyl, pyrazinyl, pyrimidinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, isoxazolyl, and oxazolyl.
- a heteroaryl group can be unsubstituted or substituted with one or more suitable substituents.
- 6-10 membered bicyclic ring indicates a saturated bi-cyclic ring with 6-7-8-9 or 10 atoms.
- Such saturated bi-cyclic ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- 6-10 membered bicyclic ring examples includeanl,4-dioxa-8- azaspiro[4.5] decyl moiety indicating a group with structural formula a 6-Oxa-2-azaspiro[3.4]octane moiety indicating a group with structural formula
- 6-10 membered bridged ring indicates a saturated bridged ring with 6-7-8-9 or 10 atoms.
- saturated bi-cyclic ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O.
- An example of such 6-10 membered bridged ring as used herein is -oxabicyclo[2.2.1]heptan represented by structure
- a dihydroindenyl moiety represents a group with structural formula . Such dihydroindenyl moiety can be optionally substituted with OH.
- a 2-hydroxy-2,3-dihydro-lH-indenyl moiety indicates a group with structural formula
- a tetrahydronaphtalenyl moiety represents a group with structural formula
- the attachment to the main structure may be anywhere on such moiety as long as it is chemically stable.
- pyrrolyl may be lH-pyrrolyl or 2H-pyrrolyl.
- halo and halogen are generic to fluoro, chloro, bromo or iodo. Preferred halogens are fluoro and Chloro. It should also be noted that the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable. For instance pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pentyl and 3-pentyl. Positions indicated on phenyl (e.g. ortho, meta and/or para) are indicated relative to the bond connecting the phenyl to the main structure. An example with regard to the position of R4, any location is indicated relative to the nitrogen (*) connected to the main structure:
- the salts of the compounds of formula (I) are those wherein the counter ion is pharmaceutically or physiologically acceptable.
- salts having a pharmaceutically unacceptable counter ion may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound of formula (I). All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
- the pharmaceutically acceptable or physiologically tolerable addition salt forms which the compounds of the present invention are able to form can conveniently be prepared using the appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; hemisulphuric, nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, aspartic,
- dodecylsulphuric heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric,
- salts also comprises the hydrates and the solvent addition forms that the compounds of the present invention are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
- stereochemically isomeric forms of compounds of the present invention defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess.
- chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound.
- All stereochemically isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
- stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates.
- the term 'stereoisomerically pure' concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i. e. minimum 90% of one isomer and maximum 10%) of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100% of one isomer and none of the other), more in particular, compounds or intermediates having a stereoisomeric excess of 90% up to 100%, even more in particular having a stereoisomeric excess of 94% up to 100% and most in particular having a
- enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases.
- Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.
- said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
- the diastereomeric racemates of formula (I) can be obtained separately by conventional methods. Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
- the present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium.
- Isotopes of carbon include C-13 and C-14.
- the present compounds or similar term is meant to include the compounds of general formula (I), (I*), (la) ,(Ib),(Ic) and (Id), salts, stereoisomeric forms and racemic mixtures or any subgroups thereof.
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- Ci-C 4 alkyl OH, CN, CFH 2 , CF 2 H and CF 3 ;
- Each R4 is independently selected from hydrogen, halogen, Ci-C 4 alkyloxy, Ci-C 4 alkyl, Ci-C 4 alkenyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N, such Ci-C 4 alkyl optionally substituted with OH;
- R 5 represents Ci-C 6 alkyl, CFH 2 , CF 2 H, CF 3i phenyl, pyridyl or a 3-7 membered
- saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 4 alkyloxy,
- Ci-C 4 alkyloxycarbonyl, oxo, C( 0)-Ci-C 3 alkyl, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ;
- the invention further provides compound of Formula (I)
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- Ci-C 4 alkyl OH, CN, CFH 2 , CF 2 H and CF 3 ;
- Each R4 is independently selected from hydrogen, halogen, Ci-C 4 alkyloxy, Ci-C 4 alkyl, Ci-C 4 alkenyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N, such Ci-C 4 alkyl optionally substituted with OH;
- R 5 represents Ci-Cealkyl, CFH 2 , CF 2 H, CF 3i phenyl, pyridyl or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 4 alkyloxy,
- Ci-C 4 alkyloxycarbonyl, oxo, C( 0)-Ci-C 3 alkyl, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ; or a pharmaceutically acceptable salt or a solvate thereof.
- At least one R 4 represents Fluor, and one other R 4 is selected from the group consisting of Ci-C 3 alkyl, Ci-C 3 alkenyl, CHF 2 or cyclopropyl.
- one R 4 represents Fluor and one other R 4 is selected from the group consisting of methyl or CHF 2i preferably methyl, and wherein the location of said Fluor is on the para position and the location of said methyl or CHF 2 is on the meta position related to the Nitrogen(*) as indicated In Formula (I*) below.
- the invention provides compound of Formula (I) wherein at least one R 4 represents Fluor, and one other R 4 is selected from the group consisting of Ci-C 3 alkyl, Ci-C 3 alkenyl, CHF 2 or cyclopropyl; more preferably, one R 4 represents Fluor and one other R 4 is selected from the group consisting of methyl or CHF 2 and wherein the location of said Fluor is on the para position and the location of said methyl or CHF 2 is on the meta position related to the Nitrogen (*) and R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyl- oxy, Ci-C 4 alkyloxycarbonyl, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 4 alkyloxy, Ci-C 4 alkyloxycarbonyl,
- a preferred substituent for such a 4-7 membered saturated ring containing carbon and one or more oxygen atoms is Ci-C 4 alkyl.
- the saturated ring is a 4, 5 or 6 membered ring.
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more nitrogen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 4 alkyloxy, Ci-C 4 alkyloxycarbonyl ,
- R 2 represents a 4-7 membered saturated ring containing carbon and one or more oxygen atoms, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 4 alkyloxy, Ci-C 4 alkyloxycarbonyl, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 wherein such compound is not
- Ci-C 6 alkyl-R 5 or Ci-C 6 alkyl is independently selected from the group consisting of hydrogen, Fluoro, OH, Ci-C 3 alkyl and CF 3 , most preferably from the group consisting of hydrigen Ci-C 3 alkyl, Fluoro and CF 3 .
- compounds according to Formula (I) are provided wherein B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 .
- R ls R 2 , R4 are defined as in any one of the embodiments as described and R 3 is selected from the group comprising hydrogen, halogen, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- R3 represents Fluor or hydrogen, more preferably hydrogen.
- R l s R 2 and R4 are defined as in any one of the embodiments as described.
- R l s R 2 and R4 are defined as in any one of the embodiments described and R3 is selected from the group comprising hydrogen, halogen, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- the compounds according to the invention are envisioned for use in the prevention or treatment of an HBV infection in a mammal.
- the present invention provides compounds which can be represented by Formula (I):
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- Each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected
- the invention relates to compounds according to Formula (I)
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- Each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;
- the present invention additionally relates to compound of Formula (I) or a stereoisomer or tautomeric form thereof, or a pharmaceutically acceptable salt or a solvate thereof
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- Each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;
- R 5 represents Ci-Cealkyl, CFH 2 , CF 2 H, CF 3 or a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo,
- Ci-C 4 alkyl OH, CN, CFH 2 , CF 2 H and CF 3 ;
- R l s R 2 , B are defined as above and each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N.
- R 2 represents a 3-7 membered saturated ring, containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- B represents phenyl or thiophene, optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 .
- At least one R4 represents Fluor, Ci-C 3 alkyl, CHF 2 or cyclopropyl.
- at least one R4 represents methyl, /-propyl or cyclopropyl.
- one R4 represents methyl, /-propyl or cyclopropyl and the other R4 represents Fluor, or hydrogen.
- the position of R4 preferably is meta and/or para (position indicated from -N ⁇ ).
- One specific embodiment is a compound of Formula (I) wherein one R4 on the para position represents Fluor and the other one R4 on the meta position represents Fluor or methyl (position indicated from -N ⁇ ).
- R l s R 2 , R4 are defined as above and R 3 is selected from the group comprising hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- R 3 represents Fluor or hydrogen.
- the invention further relates to compounds according to Formula (I)
- B represents a monocyclic 5 to 6 membered aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 5 to 6 membered aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H and CF 3 ;
- Ri represents hydrogen or Ci-C 3 alkyl
- R 2 represents Ci-C 3 alkyl-R 6 or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3;
- Each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 , HC ⁇ C or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;
- R 6 represents a 4-7 membered saturated ring optionally containing one or more
- heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ;
- R l s R 2 , B are defined as above and each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N.
- R 2 represents Ci-C 3 alkyl-R6 or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- B represents phenyl or thiophene, optionally being substituted with one or more substituents each
- At least one R 4 represents Fluor, Ci-C 3 alkyl ,CHF 2 or cyclopropyl.
- at least one R 4 represents methyl, /-propyl or cyclopropyl.
- one P represents methyl, /-propyl or cyclopropyl and the other R4 represents Fluor, or hydrogen.
- the position of R4 preferably is meta and/or para.
- One specific embodiment is a compound of Formula (I) wherein one R4 on the para position represents Fluor and the other one R4 on the meta position represents Fluor or methyl.
- Ri represents hydrogen or Ci-C 3 alkyl
- R 2 represents Ci-C 3 alkyl-R6 or a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3;
- Each R4 is independently selected from hydrogen, halo, Ci-C 4 alkyloxy, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H, CF 3 or a 3-5 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O and N;
- Re represents a 4-7 membered saturated ring optionally containing one or more
- heteroatoms each independently selected from the group consisting of O or S, such
- 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 ;
- R 3 is selected from the group comprising hydrogen, halo, Ci-C 3 alkyl, CN, CFH 2 , CF 2 H, CF 3 .
- R 3 represents Fluor or hydrogen.
- R ⁇ represents a 4-7 membered saturated ring consisting of carbon atoms and one or more heteroatoms each independently selected from the group consisting of O or S, such 4-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halo, Ci-C 4 alkyloxy, oxo, Ci-C 4 alkyl, OH, CN, CFH 2 , CF 2 H and CF 3 .
- Preferred compounds according to the invention are compounds or a stereoisomer or tautomeric form thereof with a formula or reference to a formula selected from the following tables 1 and 2: Table 2.
- the present invention concerns a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a compound of Formula (I) as specified herein, and a pharmaceutically acceptable carrier.
- a prophylactically effective amount in this context is an amount sufficient to prevent HBV infection in subjects being at risk of being infected.
- a therapeutically effective amount in this context is an amount sufficient to stabilize HBV infection, to reduce HBV infection, or to eradicate HBV infection, in infected subjects.
- this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically or prophylactically effective amount of a compound of Formula (I), as specified herein.
- compositions of the present invention may be formulated into various pharmaceutical forms for administration purposes.
- compositions there may be cited all compositions usually employed for systemically administering drugs.
- an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharma- ceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- a pharma- ceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
- any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed.
- the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
- injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
- injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
- solid form preparations intended to be converted, shortly before use, to liquid form preparations.
- the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
- the compounds of the present invention may also be administered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage.
- Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required
- unit dosage forms are tablets (including scored or coated tablets), capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
- the compounds of Formula (I) are active as inhibitors of the HBV replication cycle and can be used in the treatment and prophylaxis of HBV infection or diseases associated with HBV.
- the latter include progressive liver fibrosis, inflammation and necrosis leading to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.
- the compounds of Formula (I) or any subgroup thereof are useful in the inhibition of the HBV replication cycle, in particular in the treatment of warm-blooded animals, in particular humans, infected with HBV, and for the prophylaxis of HBV infections.
- the present invention furthermore relates to a method of treating a warm-blooded animal, in particular human, infected by HBV, or being at risk of infection by HBV, said method comprising the administration of a therapeutically effective amount of a compound of Formula (I).
- the compounds of Formula (I), as specified herein, may therefore be used as a medicine, in particular as medicine to treat or prevent HBV infection.
- Said use as a medicine or method of treatment comprises the systemic administration to HBV infected subjects or to subjects susceptible to HBV infection of an amount effective to combat the conditions associated with HBV infection or an amount effective to prevent HBV infection.
- the present invention also relates to the use of the present compounds in the manufacture of a medicament for the treatment or the prevention of HBV infection.
- an antiviral effective daily amount would be from about 0.01 to about 50 mg/kg, or about 0.01 to about 30 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing about 1 to about 500 mg, or about 1 to about 300 mg, or about 1 to about 100 mg, or about 2 to about 50 mg of active ingredient per unit dosage form.
- the present invention also concerns combinations of a compound of Formula (I) or any subgroup thereof, as specified herein with other anti-HBV agents.
- the term "combination” may relate to a product or kit containing (a) a compound of Formula (I), as specified above, and (b) at least one other compound capable of treating HBV infection (herein designated as anti-HBV agent), as a combined preparation for simultaneous, separate or sequential use in treatment of HBV infections.
- anti-HBV agent a compound capable of treating HBV infection
- the invention concerns combination of a compound of Formula (I) or any subgroup thereof with at least one anti-HBV agent.
- the invention concerns combination of a compound of formula (I) or any subgroup thereof with at least two anti-HBV agents.
- the invention concerns combination of a compound of formula (I) or any subgroup thereof with at least three anti-HBV agents. In a particular embodiment, the invention concerns combination of a compound of formula (I) or any subgroup thereof with at least four anti-HBV agents.
- anti-HBV agents such as interferon-a (IFN-a), pegylated interferon-a, 3TC, adefovir or a combination thereof, and, a compound of formula (I) or any subgroup thereof can be used as a medicine in a combination therapy.
- IFN-a interferon-a
- 3TC pegylated interferon-a
- adefovir a compound of formula (I) or any subgroup thereof
- a compound of formula (I) or any subgroup thereof can be used as a medicine in a combination therapy.
- a carboxylic acid chloride of general Formula II can be selectively reacted with an aniline of general formula III, for example in an organic solvent like CH 2 CI 2 in the presence of an organic base like triethylamine or DIPEA (N,N-diisopropylethylamine), or, as another example, by addition of the aniline III to a refluxing toluene solution of compound II, resulting in compound IV.
- the remaining sulfonic acid chloride functionality in compound IV is further reacted with an amine of general formula V, resulting in a compound of general Formula (I).
- a compound of general Formula (I) might be obtained as described in scheme 2.
- the sulfonic acid chloride VI is reacted with an amine of general formula V, for example in an organic solvent like CH 2 CI 2 in the presence of an organic base like triethylamine or DIPEA or or, as another example, in the presence of Na 2 C0 3 in a mixture of H 2 O/THF.
- the formed compound VII is coupled with aniline of general formula III in the presence of an activating reagent like for example HATU and an organic base like triethylamine or DIPEA.
- compound IV can be reacted with an amino acid XI, in the presence of a base like NaOH, resulting in compound XII as described in scheme 4.
- This intermediate XII can then optionally be cyclised to compound XIII for example by heating with acetic anhydride and KOAc in toluene, or converting the carboxylic acid to an acid chloride followed by cyclisation in the presence of a base like triethylamine.
- Suitable examples of amino acids of structure XI are derivatives of 5-aminopentanoic acid or 4-aminobutanoic acid
- a synthetic route to compounds of general formula XVI is described in Scheme 5.
- a aminoethanol derivative XIV, prepared as described in scheme 1 for the compounds of general Formula (I), is transformed in a aziridine derivative XV by treatement with Diethyl diazene-l,2-dicarboxylate and PPh 3 in THF.
- the aziridine of general formula XV is reacted with a nucleophile Nu, resulting in a compound of general formula XVI.
- nucleophiles (Nu) are, but are not limited to, morpholine and 1-methylpiperazine.
- Examples of a compound synthesized according to the route described in scheme 5, are compounds 116 and 117.
- An alternative method for the synthesis of compounds of general formula VII is via ester XVII as described in scheme 6.
- Reaction of XVII with amine V for example in an organic solvent like CH 2 CI 2 or THF in the presence of an organic base like for example triethylamine or DIPEA, followed by hydrolysis of the ester, for example with LiOH in THF/H 2 0, followed by acidification, results in a compound of general formula VII.
- a compound of general formula VII, obtained via the route in scheme 2 or scheme 6, can be transformed to and acid chloride of formula XIX, for example by treatement with oxalyl chloride or thionyl chloride.
- a compound of general formula XIX can then be transformed to a compound of general Formula (I) by reaction with an aniline of general formula III.
- a compound of general formula VI can be converted to a compound of general formula II, for example by treatement with oxalyl chloride in CH 2 CI 2 .
- compounds of general formula XXV or XXIV may be converted to compound of general formula XVII and VI respectively, by conversion to the corresponding diazonium salts (for example by NaN0 2 /HCl), followed by conversion of the diazonium salt to a sulfonyl chloride (for example by S0 2 /CuCl)(for example as described in Organic Process Research & Development, 13(5), 875-879; 2009).
- compounds of general formula XXII and XXIII (with P 7 equaling H, benzyl or methyl) may be converted to compound of general formula XVII and VI respectively, for example by treatement with Cl 2 or N- Chlorosuccinimide in AcOH/H 2 0.
- R4 in this general synthesis section are meant to include any substituent or reactive species that is suitable for transformation into any R4 subsitutent according to the present invention without undue burden for the person skilled in the art.
- Method A mobile phase A : H 2 0 (0.1%TFA; B:CH 3 CN (0.05% TFA) Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5
- Method B mobile phase A : H 2 0 (0.1%TFA; B:CH 3 CN (0.05% TFA) Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [90/10] to 0.8 [90/10] to 4.5 [20/80] to 7.5 [20/80] to 8.0 [90/10]; flow: 0.8 mL/min; column temp.: 50°C, YMC-PACK ODS-AQ, 50x2.0mm 5 ⁇
- Method C mobile phase A : H 2 0 (0.1 % TFA); B:CH 3 CN (0.05 % TFA) Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [90/10] to 0.8 [90/10] to 4.5 [20/80] to 7.5 [20/80]; 9.5 [90/10] flow: 0.8 mL/min; column temp.: 50°C; Agilent TC-C18, 50x2. lmm, 5 ⁇
- Method D mobile phase A : H 2 0 (0.05 % NH 3 .H 2 0 ); B: CH 3 CN Stop Time : 10 min; gradient time(min) [%A/%B] 0.0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5 [40/60]; 8 [100/0] flow: 0.8 mL/min; column temp.: 40 °C, XBridge Shield-RP18, 50*2. lmm 5 ⁇
- Method E mobile phase A : H 2 0 (0.1%TFA; B:CH 3 CN (0.05% TFA) Stop Time : 10 min; Post Time: 0.5 min; gradient time(min) [%A/%B]0 [100/0] to 1 [100/0] to 5 [40/60] to 7.5 [15/85] to 9.5 [100/0]; flow: 0.8 mL/min; column temp.: 50°C, Agilent TC-C18, 50x2.1mm, 5 ⁇
- Method F The LC measurement was performed using an Acquity UPLC (Waters) system with column heater (set at 55 °C). Reversed phase UPLC (Ultra Performance Liquid Chromatography) was carried out on a bridged ethylsiloxane/silica hybrid (BEH) C18 column (1.7 ⁇ , 2.1 x 50 mm; Waters Acquity) with a flow rate of 0.8 mL/min. Two mobile phases (10 mM ammonium acetate in H 2 0/acetonitrile 95/5; mobile phase B: acetonitrile) were used to run a gradient condition from 95 % A and 5 % B to 5 % A and 95 % B in 1.3 minutes and hold for 0.3 minutes. An injection volume of 0.5 ⁇ was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- Method G The LC measurement was performed using an Acquity UPLC (Waters) with column heater (set at 55 °C). Reversed phase UPLC (Ultra Performance Liquid
- Method H Reversed phase HPLC was carried out on an Atlantis CI 8 column (3.5 ⁇ , 4.6 x 100 mm) with a flow rate of 1.6 mL/min. Column heater was set at 45 °C. Two mobile phases (mobile phase A: 70 % methanol + 30 % H 2 0; mobile phase B: 0.1 % formic acid in H 2 0/methanol 95/5) were employed to run a gradient condition from 100 % B to 5 % B + 95 % A in 9 minutes and hold these conditions for 3 minutes. An injection volume of 10 ⁇ was used. Cone voltage was 10 V for positive ionization mode and 20 V for negative ionization mode.
- the residue was purified by column chromatography over silica gel (gradient eluent: petroleum ether/ethyl acetate from 100/0 to 10/90). The pure fractions were collected and the solvent was removed in vacuo. The residue was further purified by preparative high performance liquid chromatography over RP-18 (eluent: CH 3 CN in H 2 0 from 40% to 80%, v/v; 0.06% NH 4 HC0 3 as addition). The pure fractions were collected and the volatiles were removed in vacuo. The aqueous layer was lyophilized to dryness resulting in compound 9 (0.48 g) Method A; Rt: 4.6 min.
- N-Ch I orosucc i n i mi do (2.56 g, 19.2 mmol ) was added to a mixture of 2-(benzylthio)-N-phenylisonicotinamide (1.5 g, 4.68 mmol) in acetic acid (20 mL) and water (10 mL). The reaction mixture was stirred at room temperature for 4 hours. The reaction was diluted with CH 2 CI 2 (20 mL). After washing with water, the organic layer was added to the mixture of cyclohexanamine (4.64 lg, 46.8 mmol) and Et 3 N (10 mL, 71.74 mmol) in CH 2 CI 2 (50mL). The resulting mixture was stirred at room temperature for 4 hours. The reaction mixture was washed with NH 4 CI
- HATU (0.76 g, 2.0 mmol) was then added to a mixture of 4-(N-cyclohexylsulfamoyl)- picolinic acid (380 mg, 1.34 mmol), aniline (251 mg, 2.7 mmol) and DIPEA (0.517 g, 4.0 mmol) in DMF (50 mL) at room temperature The resulting mixture was stirred at room temperature for 18 hour. The mixture was diluted with water (200 mL), and extracted with EtOAc. The organic layers were washed with brine, dried over MgS0 4 , filtered and concentrated in vacuo.
- the mixture B was added portionwise to the mixture A over 30 minutes, maintaining temperature at -5°C to 0°C.After stirring at 0°C for 1 hour, the solid was collected by filtration, washed with water, and dried in vacuo resulting in 5-(chlorosulfonyl)nicotinic acid (1.05 g).
- reaction mixture was filtered through celite. Water (10 mL) was added to the filtrate and the mixture was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were washed with brine and dried over Na 2 S0 4 . The solvent was removed in vacuo. The residue was purified by preparative high
- N-(4-fluoro-3-((trimethylsilyl)ethynyl)phenyl)-3-(N-isopropylsulfamoyl)benzamide (0.8g, 1.66mmol) and TFA (4 mL) were dissolved in anhydrous CH 2 CI 2 (16 mL). The mixture was stirred at 25° overnight. The mixture was concentrated resulting in crude N-(3-ethynyl-4-fluorophenyl)-3-(N-isopropylsulfamoyl)benzamide which was used as such in the next step (650 mg).
- the reaction mixture was diluted with ethyl acetate (20 mL) and the catalyst was filtered off. The filtrate was concentrated in vacuo. Water (20 mL) was added and the aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine and dried over Na 2 S0 4 . The solvent was removed in vacuo and the obtained residue was purified by preparative high performance liquid chromatography over reversed phase C-18 (eluent: CH 3 CN in H 2 0 (0.1 % TFA) from 40% to 70%, v/v). The pure fractions were collected and the organic solvent was removed in vacuo.
- N-(4-fluoro-3-(prop-l-en-2-yl)phenyl)-3-(N-iso- propylsulfamoyl)benzamide 300 mg.
- N-(4-fluoro-3-(prop-l-en-2-yl)phenyl)-3- (N-isopropylsulfamoyl)benzamide (180 mg) and Pd/C(wet) (20 mg) were stirred in methanol (4 mL) under a hydrogen atmosphere at 25°C for 3 hours. The mixture was filtered over celite and the filtrate was evaporated to dryness in vacuo.
- 3-methyloxetan-3-amine hydrochloride (210 mg, 1.7 mmol) and NaOH (204 mg, 5.1 mmol) were dissolved in 2-methyltetrahydrofuran (5 mL) and H 2 0 (5 mL).
- Compound 224 was prepared similarly as described for compound 223, using l-(4- pyridyl)propan-2-amine instead of l-(2-pyridyl)propan-2-amine.
- Compound 224 was purified by preparative high-performance liquid chromatography (column: Luna 150*30mm*4u, mobile phase: CH 3 CN in water (0.05% NH 4 HC0 3 ) from 40% to 70%). Method A; Rt: 4.6 min. m/z: 428.3 (M+H) + Exact mass: 427.1.
- Oxalyl chloride (18.3 mL, 213 mmol) was added in four portions over one hour.
- Procedure SI A solution of 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (0.50 g, 1.52 mmol, 1 eq) in toluene (10 mL) was added to a flask containing an amine (1.1 eq). DIPEA (657 ⁇ , 3.81 mmol, 2.5 eq) was added and the reaction mixture was stirred for 1 hour. Next, 1M HC1 (5 mL) was added to the reaction mixture.
- Procedure S2 A tube was charged with 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]- benzenesulfonyl chloride (250 mg, 0.76 mmol) and an amine (1.1 eq) and CH 2 C1 2 (5 mL) was added. The solution was stirred, DIPEA (329 ⁇ , 1.9 mmol, 2.5 eq) was added and the mixture was further stirred for 30 minutes. Then, HC1 (1M aq / 5 mL) was added and the mixture was stirred for 5 minutes more.
- Workup W3 The layers were separated and the organic layer was loaded on a silica gel column for purification (with gradient elution: CH 2 Cl 2 -methanol 100:0 to 97:3).
- Workup W4 The organic layer was separated and loaded on a silica gel column. The mixture was purified using gradient elution from heptane to EtOAc.
- Cis Enantiomers 134a and 134b N-(4-fluoro-3-methyl-phenyl)-3- [[(lR,3S)-3-hydroxycyclohexyl]sulfamoyl]benzamide or N-(4-fluoro-3-methyl- phenyl)-3-[[(lS,3R)-3-hydroxycyclohexyl]sulfamoyl]benzamide.
- 141a, 141c N-(4-fiuoro-3-methyl-phenyl)-3-[[(lS,2S)-l-hydroxyindan-2-yl]- sulfamoyl]benzamide or N-(4-fluoro-3-methyl-phenyl)-3-[[(lR,2R)-l-hydroxyindan-2- yl]sulfamoyl]benzamide.
- 141b, 141d N-(4-fluoro-3-methyl-phenyl)-3-[[(li?,25)-l-hydroxyindan-2- yl]sulfamoyl]benzamide or N-(4-fluoro-3 -methyl-phenyl)-3 - [ [( 1 S ,2R)- 1 -hydroxyindan- 2-yl]sulfamoyl]benzamide.
- Racemic compound 179 was separated in enantiomers 179a and 179b by Preparative SFC (Stationary phase: Chiralpak Diacel AD 30 x 250 mm), Mobile phase: C0 2 , iPrOH with 0.4% iPrNH 2 ) The collected fractions were concentrated in vacuo resulting in compound 179a and 179b.
- 179a +6.1 ° (589 nm, c 0.6225 w/v %, MeOH, 20 °C).
- 179b -6.1 ° (589 nm, c 0.506 w/v %, MeOH, 20°C).
- 3-(isopropylsulfamoyl)benzoic acid 250 mg, 1.03 mmol
- 4-fluoro-3,5-dimethyl- aniline 157 mg, 1.13 mmol
- DIPEA 398 mg, 3.08 mmol
- acetonitrile 10 mL
- HATU 430 mg, 1.13 mmol
- EtOAc 100 mL was added and the mixture was washed with 1M HC1, sat NaHC0 3 and brine.
- the reaction mixture was poured into H 2 0 (850 mL), and EtOAc (300 mL) was added. The mixture was stirred vigorously for 5 minutes. Both upper liquid layers were decanted from a residue. The separated water layer was combined with the residue, and extracted with EtOAc. Both upper liquid layers were decanted from the residue. The separated water layer was combined with the residue, and extracted again with EtOAc. The organic layers were combined, washed with satured NaCl and dried with Na 2 S0 4 , filtered off, evaporated, and co-evaporated with toluene.
- the separated waterlayer was acidified with IN HC1 (30 mL), and the product was extracted with 2-MeTHF.
- the separated waterlayer was acidified further till pH ⁇ 2 and extracted with 2-MeTHF.
- the organic layer was washed with brine, dried with Na 2 S0 4 and filtered, resulting in crude 5-bromo-2-fluoro-6-methyl-3-[[(3S)-tetrahydrofuran-3- yl]sulfamoyl]benzoic acid (6.5 g).
- Triethylamine (0.206 mL, 0.00149 mol ) was added to a stirring mixture of 2-fluoro-6- methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid (0.15 g, 0.000495 mol ) and CH 3 CN (10 mL ) under N 2 -atm.
- HATU 0.207 g, 0.545 mmol
- 5-amino-2-fluorobenzonitrile (79.9 mg, 0.569 mmol ) was added, and the reaction mixture was stirred at room temperature for 20 hours. The reaction was next continued at 50°C for 4 hours.
- Compound 192 was prepared similarly as described for compound 191, using 3-chloro- 4,5-dif uoro-aniline hydrochloride instead of 5-amino-2-fluorobenzonitrile.
- 3-(tert-butylsulfamoyl)-2-fluoro-6-methyl-benzoic acid was prepared similarly as described for 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid, using tert-butylamine instead of 3-methyloxetan-3-amine.
- Compound 205 was prepared similar as described for compound 194, using 4-fluoro-3-methylaniline instead of 3,4- difluoroaniline and starting from 3-(tert-butylsulfamoyl)-2-fluoro-6-methyl-benzoic acid instead of 2-fluoro-6-methyl-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid.
- 2-bromo-6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid and 6-bromo-2- fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid were prepared similarly as described for 2-chloro-6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid and 6- chloro-2-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid, starting from 2- bromo-6-fluorobenzoic acid instead of 2-chloro-6-fluorobenzoic acid.
- Compound 212 was prepared similarly as described for compound 196 using 2-bromo- 6-fluoro-3-[(3-methyloxetan-3-yl)sulfamoyl]benzoic acid instead of 2,6-difluoro-3- [[(35)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid and 4-fluoro-3- (trifluoromethyl)aniline instead of 3,4-difluoroaniline.
- 3-methyl-3-oxetanamine (580 mg, 6.66 mmol) was added dropwise to the above solution at room temperature.
- Et 3 N (2.10 mL 15.14 mmol) was then added dropwise to the reaction mixture and the reaction mixture was stirred at room temperature for 45 minutes. The solvent was evaporated and the residue was taken up in EtOAc.
- HC1 (0.5 N, 30 mL) was added to the reaction mixture and the layers were separated. The organic layer was washed again with NaOH (0.5 N, 30 mL).
- 3-methyloxolan-3-amine hydrochloride (165.9 mg, 1.21 mmol) was added to a solution of 3-[(4-fluoro-3-methyl-phenyl)carbamoyl]benzenesulfonyl chloride (499 mg, 1.096 mmol) in dry CH 2 CI 2 (20 mL) at room temperature.
- Et 3 N (381 ⁇ ) was then added dropwise to the reaction mixture and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc (250 mL).
- Compound 232 to 239 were prepared by slow addition of an aniline to a refluxing toluene solution of a 3-chlorosulfonylbenzoyl chloride derivative, followed by reaction with an amine in the presence of a base like NEt 3 or DIPEA, as described above.
- the anti-HBV activity was measured using a stable transfected cell line
- HepG2.2.15 This cell line was described to secrete relatively consistent high levels of HBV virion particles, which have been shown to cause both acute and chronic infection and disease in chimpanzees.
- antiviral activity was determined by quantification of purified HBV DNA from secreted virions using realtime PCR and an HBV specific primer set and probe.
- Cytotoxicity of the compounds was tested in HepG2 cells using CellTiter-Blue, with the same incubation period and dose range as in the HepG2.2.15 assay.
- the anti HBV activity was also measured using the HepG2.117 cell line, a stable, inducibly HBV producing cell line, which replicates HBV in the absence of doxicycline (Tet-off system).
- HBV replication was induced, followed by a treatment with serially diluted compound in 96-well plates in duplicate. After 3 days of treatment, the antiviral activity was determined by quantification of intracellular HBV DNA using realtime PCR and an HBV specific primer set and probe.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201590457A EA038942B1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CN201380044856.2A CN104812743A (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US14/423,963 US10676429B2 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
KR1020217019832A KR20210081451A (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
AU2013307331A AU2013307331A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
KR1020207016380A KR102271574B1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
UAA201502767A UA123256C2 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CA2880699A CA2880699A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
BR112015004192-2A BR112015004192B1 (en) | 2012-08-28 | 2013-08-28 | sulfamoyl-arylamides, pharmaceutical composition that comprises them and their use in the treatment of hepatitis b |
KR1020157005867A KR102122357B1 (en) | 2012-08-28 | 2013-08-28 | SUlfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
AP2015008249A AP2015008249A0 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
MX2015002696A MX2015002696A (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b. |
JP2015529005A JP6505013B2 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B |
EP13756110.6A EP2890688A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
SG11201501359TA SG11201501359TA (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
NZ704748A NZ704748A (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
IL236967A IL236967A0 (en) | 2012-08-28 | 2015-01-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
CR20150060A CR20150060A (en) | 2012-08-28 | 2015-02-09 | SULFAMOYLARILAMIDS AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B. |
PH12015500317A PH12015500317A1 (en) | 2012-08-28 | 2015-02-13 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
HK15109247.5A HK1208465A1 (en) | 2012-08-28 | 2015-09-21 | Sulfamoyl arylamides and the use thereof as medicaments for the treatment of hepatitis b |
IL253225A IL253225B (en) | 2012-08-28 | 2017-06-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
AU2018204597A AU2018204597B2 (en) | 2012-08-28 | 2018-06-25 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
PH12019502355A PH12019502355A1 (en) | 2012-08-28 | 2019-10-16 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
AU2020201203A AU2020201203A1 (en) | 2012-08-28 | 2020-02-19 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
US16/858,519 US20200255373A1 (en) | 2012-08-28 | 2020-04-24 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12182076 | 2012-08-28 | ||
EP12182076.5 | 2012-08-28 | ||
EP12185055 | 2012-09-19 | ||
EP12185055.6 | 2012-09-19 | ||
EP12190837.0 | 2012-10-31 | ||
EP12190837 | 2012-10-31 | ||
EP13157230.7 | 2013-02-28 | ||
EP13157230 | 2013-02-28 | ||
EP13169574 | 2013-05-28 | ||
EP13169574.4 | 2013-05-28 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/423,963 A-371-Of-International US10676429B2 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US16/858,519 Continuation US20200255373A1 (en) | 2012-08-28 | 2020-04-24 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014033170A1 true WO2014033170A1 (en) | 2014-03-06 |
Family
ID=49085019
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/067829 WO2014033176A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
PCT/EP2013/067821 WO2014033170A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/067829 WO2014033176A1 (en) | 2012-08-28 | 2013-08-28 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
Country Status (27)
Country | Link |
---|---|
US (5) | US20150274653A1 (en) |
EP (2) | EP2890688A1 (en) |
JP (5) | JP2015533782A (en) |
KR (4) | KR102271574B1 (en) |
CN (4) | CN104812743A (en) |
AP (2) | AP2015008248A0 (en) |
AR (2) | AR092269A1 (en) |
AU (5) | AU2013307337B2 (en) |
BR (2) | BR112015004192B1 (en) |
CA (2) | CA2881057C (en) |
CL (2) | CL2015000487A1 (en) |
CR (2) | CR20210079A (en) |
EA (2) | EA027280B1 (en) |
EC (2) | ECSP15007335A (en) |
GT (2) | GT201500021A (en) |
HK (2) | HK1208465A1 (en) |
IL (3) | IL236967A0 (en) |
JO (1) | JOP20130256B1 (en) |
MX (2) | MX2015002696A (en) |
NI (2) | NI201500029A (en) |
NZ (4) | NZ704752A (en) |
PH (3) | PH12015500317A1 (en) |
SG (4) | SG11201501359TA (en) |
TW (4) | TW201920090A (en) |
UA (2) | UA123256C2 (en) |
UY (2) | UY34992A (en) |
WO (2) | WO2014033176A1 (en) |
Cited By (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014184365A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9061008B2 (en) | 2011-12-21 | 2015-06-23 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
KR20160008574A (en) * | 2013-05-17 | 2016-01-22 | 얀센 사이언시즈 아일랜드 유씨 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US20160185748A1 (en) * | 2014-12-30 | 2016-06-30 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for hbv treatment |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
WO2016149581A1 (en) * | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
WO2017048962A1 (en) | 2015-09-15 | 2017-03-23 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
WO2017205115A1 (en) | 2016-05-27 | 2017-11-30 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
WO2017205078A1 (en) | 2016-05-27 | 2017-11-30 | Gilead Sciences, Inc. | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
US9890167B2 (en) | 2015-01-16 | 2018-02-13 | Hoffmann-La Roche Inc. | Pyrazine compounds for the treatment of infectious diseases |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2018039531A1 (en) | 2016-08-26 | 2018-03-01 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
AU2014222641B2 (en) * | 2013-02-28 | 2018-03-15 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
WO2018053157A1 (en) | 2016-09-15 | 2018-03-22 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
US9938236B2 (en) | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
WO2018085619A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma, Inc. | Substituted pyridinone-containing tricyclic compounds, and methods using same |
WO2018144605A1 (en) | 2017-02-02 | 2018-08-09 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
WO2018144390A1 (en) | 2017-01-31 | 2018-08-09 | Gilead Sciences, Inc. | Crystalline forms of tenofovir alafenamide |
WO2018160090A1 (en) | 2017-02-28 | 2018-09-07 | Александр Васильевич ИВАЩЕНКО | Antiviral composition and method for using same |
WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
RU2666727C1 (en) * | 2017-07-18 | 2018-09-12 | Андрей Александрович Иващенко | Hepatitis b (hbv) inhibitor |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
WO2018195321A1 (en) | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
WO2019040102A1 (en) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2019086142A1 (en) | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2019086141A1 (en) | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
WO2019166532A1 (en) | 2018-03-01 | 2019-09-06 | Janssen Sciences Ireland Unlimited Company | 2,4-diaminoquinazoline derivatives and medical uses thereof |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
WO2019193542A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides |
WO2019193533A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2'-cyclic dinucleotides |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
WO2019200247A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
EP3590943A1 (en) | 2015-07-02 | 2020-01-08 | Janssen Sciences Ireland Unlimited Company | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2020010200A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2020010223A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2020014643A1 (en) | 2018-07-13 | 2020-01-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
EP3607950A2 (en) | 2014-03-13 | 2020-02-12 | Indiana University Research & Technology Corporation | Hepatitis b core protein allosteric modulators |
US10562905B2 (en) | 2016-07-14 | 2020-02-18 | Hoffmann-La Roche Inc. | Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseases |
US10604527B2 (en) | 2016-05-20 | 2020-03-31 | Hoffmann-La Roche Inc. | Pyrazine compounds for the treatment of hepatitis B infection |
WO2020072955A1 (en) * | 2018-10-05 | 2020-04-09 | Emory University | Monomer and multimeric anti-hbv agents |
WO2020086533A1 (en) | 2018-10-22 | 2020-04-30 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
WO2020087107A1 (en) | 2018-10-31 | 2020-05-07 | The University Of Sydney | Compositions and methods for treating viral infections |
WO2020089453A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020089452A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv) |
WO2020089455A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020089459A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv) |
WO2020089456A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv) |
WO2020089460A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
US10676429B2 (en) | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10683299B2 (en) | 2016-07-14 | 2020-06-16 | Hoffmann La Roche Inc. | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases |
WO2020123674A1 (en) | 2018-12-12 | 2020-06-18 | Arbutus Biopharma Corporation | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
US10781206B2 (en) | 2016-07-14 | 2020-09-22 | Hoffmann La-Roche Inc. | Tetrahydropyrazolopyridine compounds for the treatment of infectious diseases |
WO2020214663A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214652A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020221824A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020221816A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
WO2020221826A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020221811A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020242999A1 (en) | 2019-05-24 | 2020-12-03 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
US10934306B2 (en) | 2016-03-07 | 2021-03-02 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2021216642A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2021216656A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
WO2022087149A2 (en) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Interleukin-2-fc fusion proteins and methods of use |
US11377450B2 (en) | 2018-09-21 | 2022-07-05 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11596611B2 (en) | 2017-08-28 | 2023-03-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
EP4028394A4 (en) * | 2019-09-04 | 2023-10-11 | Taigen Biotechnology Co., Ltd. | Hepatitis b antiviral agents |
US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
US11891393B2 (en) | 2018-11-21 | 2024-02-06 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10065937B2 (en) * | 2014-07-31 | 2018-09-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | FLT3 receptor antagonists |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
WO2017011552A1 (en) | 2015-07-13 | 2017-01-19 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10280175B2 (en) | 2016-02-02 | 2019-05-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CN109843296A (en) | 2016-06-10 | 2019-06-04 | 英安塔制药有限公司 | B type hepatitis antivirus medicament |
WO2018086530A1 (en) * | 2016-11-08 | 2018-05-17 | 正大天晴药业集团股份有限公司 | Sulfonamide compound as cccdna inhibitor |
CN108264520B (en) * | 2017-01-03 | 2021-12-07 | 上海长森药业有限公司 | Compound for treating hepatitis B and application thereof |
AU2018217664B2 (en) * | 2017-02-07 | 2022-03-03 | Janssen Pharmaceutica Nv | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis |
US10428070B2 (en) | 2017-12-06 | 2019-10-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CN109879799B (en) * | 2017-12-06 | 2020-08-11 | 浙江司太立制药股份有限公司 | Sulfamoyl benzamide compound containing 4-carbonyloxypiperidine and preparation method thereof |
US10723733B2 (en) | 2017-12-06 | 2020-07-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
CN109988126B (en) * | 2017-12-29 | 2023-05-16 | 南京富润凯德生物医药有限公司 | 3-amino-oxetane derivative and preparation method and application thereof |
US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2019154343A1 (en) * | 2018-02-09 | 2019-08-15 | 正大天晴药业集团股份有限公司 | Capsid protein assembly inhibitor, and pharmaceutical composition and use thereof |
WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2019206072A1 (en) * | 2018-04-24 | 2019-10-31 | 浙江海正药业股份有限公司 | Sulfamide aryl formamide derivative and preparation method therefor and uses thereof |
EP3597637A1 (en) * | 2018-07-19 | 2020-01-22 | Irbm S.P.A. | Inhibitors of hepatitis b virus |
WO2020241814A1 (en) * | 2019-05-29 | 2020-12-03 | 国立大学法人東京大学 | ANTIVIRAL AGENT OR VIRAL cccDNA FORMATION INHIBITOR |
WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
US20220305116A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences lreland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives |
AU2020415322A1 (en) | 2019-12-24 | 2022-06-16 | F. Hoffmann-La Roche Ag | Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV |
WO2021160617A1 (en) * | 2020-02-11 | 2021-08-19 | Irbm S.P.A. | Spirocyclic inhibitors of hepatitis b virus |
CN113493441A (en) * | 2020-04-03 | 2021-10-12 | 广东东阳光药业有限公司 | Novel spiro compound and application thereof in medicines |
CN111349056B (en) * | 2020-04-16 | 2022-08-02 | 南京安纳康生物科技有限公司 | Antiviral agent for hepatitis B virus infection |
CN111393391B (en) * | 2020-04-16 | 2022-07-26 | 南京安纳康生物科技有限公司 | Antiviral agent for hepatitis B virus infection |
CN115677545B (en) * | 2022-10-28 | 2024-03-15 | 潍坊医学院 | anti-HBV sulfonamide derivative and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064618A2 (en) * | 2001-02-09 | 2002-08-22 | Massachusetts Institute Of Technology | Methods of identifying agents that mediate polypeptide aggregation |
US20050239833A1 (en) * | 2004-03-05 | 2005-10-27 | Kazantsev Aleksey G | Compositions and methods for modulating interaction between polypeptides |
US20100016310A1 (en) * | 2006-08-17 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
US20110009622A1 (en) * | 2008-04-24 | 2011-01-13 | Makoto Jitsuoka | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient |
WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
Family Cites Families (217)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1359583A (en) * | 1919-11-28 | 1920-11-23 | James W Doolittle | Force-feed oil-cup |
US1359596A (en) * | 1919-12-08 | 1920-11-23 | Pressure Proof Piston Ring Com | Piston-ring |
US3843662A (en) | 1971-12-09 | 1974-10-22 | Pfizer | 2-halo-5-(substituted piperidino sulfonyl)benzoic acids |
AU1508183A (en) | 1982-06-04 | 1983-12-08 | Beecham Group Plc | Benzamide and anilide derivatives of 8-azabicyclo-(3.2.1)- -octane |
WO1984003281A1 (en) | 1983-02-19 | 1984-08-30 | Beecham Group Plc | Azabicycloalkyl benzamide and anilide derivatives |
JPS62142164A (en) | 1985-12-13 | 1987-06-25 | Ishihara Sangyo Kaisha Ltd | 4,5-dichloroimidazole based compound and pest controlling agent containing said compound |
IN164880B (en) * | 1986-01-30 | 1989-06-24 | Ishihara Sangyo Kaisha | |
US5272167A (en) | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
CA1339133C (en) | 1987-03-13 | 1997-07-29 | Rikuo Nasu | Imidazole compounds and biocidal composition comprising the same for controlling harmful organisms |
JP2606720B2 (en) * | 1987-03-13 | 1997-05-07 | 石原産業株式会社 | Imidazole compounds and pesticides containing them |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
GB8904174D0 (en) | 1989-02-23 | 1989-04-05 | British Bio Technology | Compounds |
US4962101A (en) | 1989-08-21 | 1990-10-09 | Merck & Co., Inc. | 2-(Heterocyclylalkyl)phenyl carbapenem antibacterial agents |
GB9023082D0 (en) | 1990-10-24 | 1990-12-05 | Schering Agrochemicals Ltd | Fungicides |
GB9109557D0 (en) | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
US5308826A (en) | 1993-04-22 | 1994-05-03 | Zeneca Limited | Herbicidal 4-substituted pyridyl-3-carbinols |
GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
JPH10504525A (en) | 1994-05-27 | 1998-05-06 | ジェイムズ・ブラック・ファウンデーション・リミテッド | Gastrin and CCK antagonist |
US5795907A (en) | 1994-05-27 | 1998-08-18 | James Black Foundation Limited | Gastin and CCK receptor ligands |
KR0131723B1 (en) * | 1994-06-08 | 1998-04-14 | 김주용 | Manufacturing method for semiconductor device |
US5763618A (en) | 1995-05-12 | 1998-06-09 | Konica Corporation | Manufacturing method of sulfides |
US5723411A (en) | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
DE19540995A1 (en) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituted sulfonimidamides, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
EP0912550A1 (en) | 1996-06-25 | 1999-05-06 | Smithkline Beecham Plc | Sulfonamide derivatives as 5ht7 receptor antagonists |
WO1998023285A1 (en) | 1996-11-29 | 1998-06-04 | Smithkline Beecham Plc | Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b |
US5939423A (en) | 1997-04-16 | 1999-08-17 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US5994396A (en) * | 1997-08-18 | 1999-11-30 | Centaur Pharmaceuticals, Inc. | Furansulfonic acid derivatives and pharmaceutical compositions containing the same |
AU759255B2 (en) | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
HUP0101275A3 (en) | 1998-03-26 | 2002-12-28 | Japan Tobacco Inc | Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists |
US6251893B1 (en) | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
BR0007527B1 (en) | 1999-01-15 | 2011-12-27 | phenylphenanthridines with inhibitory activity of pde-iv, their use, as well as medicament comprising them. | |
HUP0202319A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain |
JP2003506406A (en) | 1999-08-10 | 2003-02-18 | ザ・チャンセラー・マスターズ・アンド・スカラーズ・オブ・ザ・ユニバーシティ・オブ・オックスフォード | Long-chain N-alkyl compounds and oxa derivatives thereof |
MX226123B (en) | 1999-09-17 | 2005-02-07 | Millennium Pharm Inc | BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa. |
PE20010628A1 (en) | 1999-10-01 | 2001-06-18 | Takeda Chemical Industries Ltd | CYCLIC AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE |
AP2002002565A0 (en) | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
AU2882801A (en) | 2000-01-28 | 2001-08-07 | Kaken Pharmaceutical Co., Ltd. | Azepine derivatives |
US6511980B2 (en) | 2000-05-05 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Substituted diamine derivatives useful as motilin antagonists |
EP1193268A1 (en) | 2000-09-27 | 2002-04-03 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of protein Junkinases |
WO2002051410A2 (en) | 2000-12-22 | 2002-07-04 | Akzo Nobel N.V. | Phenylthiazole and thiazoline derivatives and their use as antiparasitics |
EP1535924A1 (en) | 2000-12-27 | 2005-06-01 | Sumitomo Pharmaceuticals Company, Limited | Novel carbapenem compounds |
US6650463B2 (en) | 2001-03-13 | 2003-11-18 | Seiko Epson Corporation | Electrophoretic display device |
KR100713137B1 (en) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | Novel 2,4-difluorobenzamide derivatives |
WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
DE10136043A1 (en) | 2001-07-25 | 2003-02-13 | Degussa | Process for the production of modified carbon black |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
AU2002347982A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE Beta3 AGONISTS |
SE0201635D0 (en) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
AU2003242127A1 (en) | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
RU2340605C2 (en) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Arylcarbonyl derivatives as therapeutic agents |
JP4881559B2 (en) | 2002-06-27 | 2012-02-22 | ノボ・ノルデイスク・エー/エス | Arylcarbonyl derivatives as therapeutic agents |
WO2004010943A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
AU2003254177A1 (en) | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
JP4399862B2 (en) | 2002-08-09 | 2010-01-20 | 味の素株式会社 | Treatment for bowel disease and visceral pain |
US20040110802A1 (en) * | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
RU2005106274A (en) | 2002-09-06 | 2005-11-10 | Янссен Фармацевтика, Н.В. (Be) | HETEROCYCLIC COMPOUNDS |
SE0202838D0 (en) | 2002-09-24 | 2002-09-24 | Astrazeneca Ab | Chemical compounds |
US7378525B2 (en) | 2002-12-23 | 2008-05-27 | Millennium Pharmaceuticals, Inc. | CCR8 inhibitors |
US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
ATE524452T1 (en) | 2003-03-27 | 2011-09-15 | Cytokinetics Inc | SULFONAMIDES FOR TREATING CONGESTIVE HEART FAILURE, COMPOSITIONS AND USES THEREOF. |
JP2006525366A (en) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | Heterocyclic carboxylic acid substituent |
US7592352B2 (en) | 2003-05-06 | 2009-09-22 | Smithkline Beecham Corporation | Substituted thieno and furo-pyridines |
TW200510405A (en) | 2003-05-13 | 2005-03-16 | Schering Corp | Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors |
US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
US20110275630A1 (en) | 2003-06-02 | 2011-11-10 | Abbott Laboratories | Isoindolinone kinase inhibitors |
EP1631559A4 (en) | 2003-06-06 | 2008-08-27 | Smithkline Beecham Corp | Il-8 receptor antagonists |
AR045047A1 (en) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES |
GB0319151D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US7498050B2 (en) | 2003-12-15 | 2009-03-03 | Kraft Foods Global Brands Llc | Edible spread composition and packaged product |
DE102004009238A1 (en) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | New aryl amide compounds are kinase inhibitors useful for the treatment and/or prophylaxis of e.g. tumors, psoriasis, rheumatoid arthritis, contact dermatitis, inflammations, endometriosis, scar and benign prostatic hyperplasia |
EP1758856A2 (en) | 2004-05-04 | 2007-03-07 | Novo Nordisk A/S | Indole derivatives for the treatment of obesity |
US20090105218A1 (en) | 2004-05-29 | 2009-04-23 | 7Tm Pharma A/S | CRTH2 Receptor Ligands For Therapeutic Use |
ATE444066T1 (en) | 2004-06-22 | 2009-10-15 | Schering Corp | LIGANDS FOR THE CANNABINOID RECEPTORS |
WO2006012642A2 (en) | 2004-07-30 | 2006-02-02 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
DE102004042441A1 (en) | 2004-08-31 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Amino acid substituted hexahydro-pyrazino (1,2-a) pyrimidine-4,7-dione derivatives, process for their preparation and their use as medicaments |
CN101048388A (en) | 2004-08-31 | 2007-10-03 | 阿斯利康(瑞典)有限公司 | Quinazolinone derivatives and their use as B-Raf inhibitors |
AU2005295788A1 (en) | 2004-10-13 | 2006-04-27 | Wyeth | N-benzenesulfonyl substituted anilino-pyrimidine analogs |
MX2007004699A (en) | 2004-10-19 | 2007-06-14 | Novartis Vaccines & Diagnostic | Indole and benzimidazole derivatives. |
WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
US20060122236A1 (en) | 2004-12-06 | 2006-06-08 | Wood Michael R | Substituted biaryl-carboxylate derivatives |
WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
CA2589773A1 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Pyridine carboxamide derivatives for use as anticancer agents |
FI117653B (en) | 2005-02-21 | 2006-12-29 | Eigenor Oy | Procedure and arrangement for sensing objects with a radar |
GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
PT1940786E (en) | 2005-09-16 | 2010-10-04 | Arrow Therapeutics Ltd | Biphenyl derivatives and their use in treating hepatitis c |
EP1976829A2 (en) | 2005-12-12 | 2008-10-08 | Genelabs Technologies, Inc. | N-(6-membered aromatic ring)-amido anti-viral compounds |
MX2008008340A (en) | 2005-12-21 | 2008-09-03 | Schering Corp | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist. |
EP1981849A1 (en) | 2005-12-29 | 2008-10-22 | LEK Pharmaceuticals D.D. | Heterocyclic compounds |
EP2019830A4 (en) | 2006-05-04 | 2011-01-19 | Inst Hepatitis & Virus Res | Inhibitors of secretion of hepatitis b virus antigens for treatment of a chronic hepatitis virus |
US8153803B2 (en) * | 2006-07-18 | 2012-04-10 | The General Hospital Corporation | Compositions and methods for modulating sirtuin activity |
US20080021063A1 (en) | 2006-07-18 | 2008-01-24 | Kazantsev Aleksey G | Compositions and methods for modulating sirtuin activity |
FR2903985B1 (en) | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2904316B1 (en) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | N- (AMINO-HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
CA2665007A1 (en) | 2006-10-06 | 2008-05-08 | Merck & Co., Inc. | Non-nucleoside reverse transcriptase inhibitors |
WO2008076270A2 (en) | 2006-12-13 | 2008-06-26 | Temple University-Of The Commonwealth System Of Higher Education | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
US20100022517A1 (en) | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
FR2910473B1 (en) | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | N- (AMINO-HETEROARYL) -1H-PYRROLOPYRIDINE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
JP2008179621A (en) | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | Nitrogen-containing saturated heterocyclic compound |
US9001047B2 (en) | 2007-01-07 | 2015-04-07 | Apple Inc. | Modal change based on orientation of a portable multifunction device |
JP2008184403A (en) | 2007-01-29 | 2008-08-14 | Japan Health Science Foundation | New hepatitis c virus inhibitor |
PE20090188A1 (en) | 2007-03-15 | 2009-03-20 | Novartis Ag | HETEROCYCLIC COMPOUNDS AS MODULATORS OF THE HEDGEHOG PATH |
US8097728B2 (en) | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
EP2152688A1 (en) | 2007-05-04 | 2010-02-17 | Irm Llc | Compounds and compositions as c-kit and pdgfr kinase inhibitors |
WO2008154819A1 (en) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Carbethoxy-substituted thiazolyl dihydropyrimidines |
US8597949B2 (en) | 2007-07-28 | 2013-12-03 | The University Of Chicago | Methods and compositions for modulating RAD51 and homologous recombination |
BRPI0815038A2 (en) | 2007-08-02 | 2015-03-17 | Hoffmann La Roche | USE OF BENZAMIDE DERIVATIVES FOR TREATMENT OF CNS DISORDERS |
CN101429166B (en) | 2007-11-07 | 2013-08-21 | 上海特化医药科技有限公司 | Quinazoline ketone derivant, preparation method and application thereof |
WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
FR2926554B1 (en) | 2008-01-22 | 2010-03-12 | Sanofi Aventis | AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
FR2926556B1 (en) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
FR2926555B1 (en) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2926553B1 (en) | 2008-01-23 | 2010-02-19 | Sanofi Aventis | SILANYL SUBSTITUTED INDOLE-2-CARBOXAMIDE AND AZAINDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
CU20080028A6 (en) * | 2008-02-29 | 2011-02-24 | Ct Ingenieria Genetica Biotech | CHEMICAL COMPOUNDS OBTAINED IN SILICO FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TO ATTENE OR INHIBIT INFECTION BY DENGUE VIRUSES AND OTHER FLAVIVIRUS |
WO2009146013A1 (en) | 2008-03-31 | 2009-12-03 | Georgetown University | Myosin light chain phosphatase inhibitors |
US20090325960A1 (en) | 2008-06-26 | 2009-12-31 | Fulcher Emilee H | Method for treating inflammatory diseases using rho kinase inhibitor compounds |
US20090325959A1 (en) | 2008-06-26 | 2009-12-31 | Vittitow Jason L | Method for treating ophthalmic diseases using rho kinase inhibitor compounds |
US20100008968A1 (en) | 2008-06-26 | 2010-01-14 | Lampe John W | Method for treating cardiovascular diseases using rho kinase inhibitor compounds |
WO2009158587A1 (en) | 2008-06-26 | 2009-12-30 | Inspire Pharmaceuticals, Inc. | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
US8410147B2 (en) | 2008-06-26 | 2013-04-02 | Inspire Pharmaceuticals, Inc. | Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds |
US8207195B2 (en) | 2008-06-26 | 2012-06-26 | Inspire Pharmaceuticals, Inc. | Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds |
CA2735392A1 (en) | 2008-08-15 | 2010-02-18 | F. Hoffmann-La Roche Ag | Bi-aryl aminotetralines |
US9040488B2 (en) | 2008-09-02 | 2015-05-26 | Baruch S. Blumberg Institute | Imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity |
US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
WO2010043592A1 (en) | 2008-10-15 | 2010-04-22 | Revotar Biopharmaceuticals Ag | Lipase inhibitors for use for the treatment of obesity |
AR074199A1 (en) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | COMPOSITE OF 6- (4-PYRIMIDINYL) -1H-INDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR DECREASE OF CANCER GRAVITY. |
EP2400969A4 (en) | 2008-12-04 | 2012-05-16 | Inspire Pharmaceuticals Inc | Method for treating pulmonary diseases using rho kinase inhibitor compounds |
CA2748174A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
WO2010088000A2 (en) | 2009-02-02 | 2010-08-05 | Angion Biomedica Corp. | Antifibrotic compounds and uses thereof |
WO2010123139A1 (en) * | 2009-04-24 | 2010-10-28 | 持田製薬株式会社 | Arylcarboxamide derivative having sulfamoyl group |
WO2010133336A1 (en) | 2009-05-19 | 2010-11-25 | Bayer Cropscience Ag | Insecticidal arylpyrrolines |
TWI574961B (en) | 2009-05-27 | 2017-03-21 | Ptc治療公司 | Methods for treating cancer and non-neoplastic conditions |
AU2010266570A1 (en) | 2009-06-30 | 2012-01-19 | Siga Technologies, Inc. | Treatment and prevention of Dengue virus infections |
US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US20120252792A1 (en) | 2009-09-17 | 2012-10-04 | The Regents Of The University Of Michigan | Methods and compositions for modulating rho-mediated gene transcription |
US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
CN102093320B (en) | 2009-12-09 | 2013-08-28 | 扬子江药业集团上海海尼药业有限公司 | Soluble epoxide hydrolase inhibitor |
WO2011088015A1 (en) | 2010-01-15 | 2011-07-21 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2011088561A1 (en) | 2010-01-20 | 2011-07-28 | University Of Manitoba | Anti-viral compounds and compositions |
US20130045203A1 (en) | 2010-03-02 | 2013-02-21 | Emory University | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP |
WO2011112191A1 (en) | 2010-03-11 | 2011-09-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
CN102206172B (en) * | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | Substituted diaryl compound and preparation method and antiviral application thereof |
EP2552208A4 (en) | 2010-03-31 | 2014-07-09 | Glaxo Group Ltd | Imidazolyl-imidazoles as kinase inhibitors |
BR112012028556A2 (en) | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | INDOS |
US8993622B2 (en) | 2010-06-11 | 2015-03-31 | Eirium Ab | Antiviral compounds |
WO2011163593A2 (en) | 2010-06-25 | 2011-12-29 | Philadelphia Health & Education Corporation D/B/A Drexel | Induction of immune response |
CA2805242A1 (en) | 2010-07-19 | 2012-01-26 | Inspire Pharmaceuticals, Inc. | Bifunctional rho kinase inhibitor compounds, composition and use |
WO2012018635A2 (en) | 2010-07-26 | 2012-02-09 | Neurotherapeutics Pharma, Inc. | Arylsulfonamide derivatives, compositions, and methods of use |
CA2803689A1 (en) | 2010-07-27 | 2012-02-02 | Inspire Pharmaceuticals, Inc. | Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms |
WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
WO2012033956A1 (en) | 2010-09-08 | 2012-03-15 | Mithridion, Inc. | Cognition enhancing compounds and compositions, methods of making, and methods of treating |
WO2012047856A2 (en) | 2010-10-04 | 2012-04-12 | Institute For Hepatitis And Virus Research | Novel inhibitors of secretion of hepatitis b virus antigens |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
WO2012075235A1 (en) | 2010-12-02 | 2012-06-07 | Bristol-Myers Squibb Company | Alkyl amides as hiv attachment inhibitors |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
GB201103419D0 (en) | 2011-02-28 | 2011-04-13 | Univ Aberdeen | |
SI2694484T1 (en) | 2011-04-08 | 2018-10-30 | Janssen Sciences Ireland Uc | Pyrimidine derivatives for the treatment of viral infections |
US8889716B2 (en) | 2011-05-10 | 2014-11-18 | Chdi Foundation, Inc. | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof |
US9233933B2 (en) | 2012-01-06 | 2016-01-12 | Janssen Sciences Ireland Uc | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis B |
US9657013B2 (en) * | 2012-02-29 | 2017-05-23 | Baruch S. Blumberg Institute | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use |
WO2013144129A1 (en) | 2012-03-31 | 2013-10-03 | F. Hoffmann-La Roche Ag | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
UY34824A (en) | 2012-05-25 | 2013-11-29 | Janssen R & D Ireland | NUCLEOSIDES OF URACILO SPYROOXETHANE |
KR101945578B1 (en) | 2012-06-01 | 2019-02-07 | 드렉셀유니버시티 | Modulation of hepatitis b virus cccdna transcription |
JO3300B1 (en) | 2012-06-06 | 2018-09-16 | Novartis Ag | Compounds and compositions for modulating egfr activity |
TW201408652A (en) | 2012-07-11 | 2014-03-01 | Hoffmann La Roche | Aryl sultam derivatives as RORc modulators |
EA026957B1 (en) | 2012-08-28 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b |
EA027280B1 (en) | 2012-08-28 | 2017-07-31 | Янссен Сайенсиз Айрлэнд Юси | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
KR20150054795A (en) | 2012-09-10 | 2015-05-20 | 에프. 호프만-라 로슈 아게 | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
SG11201504740UA (en) * | 2012-12-27 | 2015-07-30 | Univ Drexel | Novel antiviral agents against hbv infection |
AU2014221775B2 (en) | 2013-02-28 | 2017-08-24 | Eisai R&D Management Co., Ltd. | TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE |
CA2899706C (en) | 2013-02-28 | 2021-10-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
EP2970340B1 (en) | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
BR112015028538A2 (en) | 2013-05-17 | 2017-07-25 | Janssen Sciences Ireland Uc | sulfamoylthiophenamide derivatives and their use as medicines for the treatment of hepatitis b |
JO3603B1 (en) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
CN105209470B (en) | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | For treating and preventing the heteroaryl dihydro-pyrimidin of 6 hepatitis b virus infected bridgings |
PE20160874A1 (en) | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | CHEMICAL COMPOUNDS |
EP3003042B1 (en) | 2013-05-28 | 2017-06-21 | Bayer CropScience Aktiengesellschaft | Heterocyclic compounds as pest controllers |
WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
NO3024819T3 (en) | 2013-07-25 | 2018-07-21 | ||
WO2015055764A1 (en) | 2013-10-18 | 2015-04-23 | Syngenta Participations Ag | 3-methanimidamid-pyridine derivatives as fungicides |
CA2927560A1 (en) | 2013-10-18 | 2015-04-23 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
JP6490686B2 (en) | 2013-11-14 | 2019-03-27 | ノヴィラ・セラピューティクス・インコーポレイテッド | Azepane derivative and method for treating hepatitis B infection |
JO3466B1 (en) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | Tetrahydropyridopyrazines modulators of gpr6 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
EP4023294A1 (en) | 2014-01-31 | 2022-07-06 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating alzheimer's disease |
RU2702109C1 (en) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Combined therapy for treating hepatitis b infections |
CN110483484A (en) | 2014-02-06 | 2019-11-22 | 爱尔兰詹森科学公司 | Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug |
PT3114128T (en) | 2014-03-07 | 2019-02-27 | Hoffmann La Roche | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
DK3116316T3 (en) | 2014-03-13 | 2019-08-19 | Univ Indiana Res & Tech Corp | ALLOSTERIC MODULATORS OF HEPATITIS B CORE PROTEIN |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
MX2016012573A (en) | 2014-03-28 | 2018-02-19 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and their application in pharmaceuticals. |
CA2950807C (en) | 2014-05-30 | 2022-05-31 | Medshine Discovery Inc. | Dihydropyrimido fused ring derivative as hbv inhibitor |
DK3227262T3 (en) | 2014-12-02 | 2020-08-10 | Novira Therapeutics Inc | SULFIDALKYL AND PYRIDYL-REVERSE SULPHONAMIDE COMPOUNDS FOR HBV TREATMENT |
US9550779B2 (en) | 2014-12-30 | 2017-01-24 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
MA41338B1 (en) | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Pyrazine compounds for the treatment of infectious diseases |
CN107847762A (en) | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection |
WO2016161268A1 (en) | 2015-04-01 | 2016-10-06 | Enanta Pharmaceuticals, Inc. | Hepatitis b antviral agents |
WO2016168619A1 (en) | 2015-04-17 | 2016-10-20 | Indiana University Research And Technology Corporation | Hepatitis b viral assembly effectors |
WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3356328A1 (en) | 2015-09-29 | 2018-08-08 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis b antiviral agent |
CN109251212A (en) | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | Inner ring sulfide amide-arylamides and its purposes for treating hepatitis B |
-
2013
- 2013-08-28 EA EA201590450A patent/EA027280B1/en unknown
- 2013-08-28 KR KR1020207016380A patent/KR102271574B1/en active IP Right Grant
- 2013-08-28 NZ NZ704752A patent/NZ704752A/en not_active IP Right Cessation
- 2013-08-28 MX MX2015002696A patent/MX2015002696A/en active IP Right Grant
- 2013-08-28 NZ NZ74346313A patent/NZ743463A/en not_active IP Right Cessation
- 2013-08-28 CA CA2881057A patent/CA2881057C/en not_active Expired - Fee Related
- 2013-08-28 BR BR112015004192-2A patent/BR112015004192B1/en not_active IP Right Cessation
- 2013-08-28 TW TW108104154A patent/TW201920090A/en unknown
- 2013-08-28 AR ARP130103056A patent/AR092269A1/en not_active Application Discontinuation
- 2013-08-28 WO PCT/EP2013/067829 patent/WO2014033176A1/en active Application Filing
- 2013-08-28 KR KR1020157005867A patent/KR102122357B1/en active IP Right Grant
- 2013-08-28 WO PCT/EP2013/067821 patent/WO2014033170A1/en active Application Filing
- 2013-08-28 AR ARP130103057A patent/AR092270A1/en not_active Application Discontinuation
- 2013-08-28 UA UAA201502767A patent/UA123256C2/en unknown
- 2013-08-28 UY UY0001034992A patent/UY34992A/en not_active Application Discontinuation
- 2013-08-28 JP JP2015529007A patent/JP2015533782A/en not_active Withdrawn
- 2013-08-28 US US14/423,981 patent/US20150274653A1/en not_active Abandoned
- 2013-08-28 KR KR1020217019832A patent/KR20210081451A/en not_active Application Discontinuation
- 2013-08-28 UY UY0001034993A patent/UY34993A/en not_active Application Discontinuation
- 2013-08-28 EP EP13756110.6A patent/EP2890688A1/en not_active Withdrawn
- 2013-08-28 EP EP13756113.0A patent/EP2890375B1/en active Active
- 2013-08-28 AP AP2015008248A patent/AP2015008248A0/en unknown
- 2013-08-28 TW TW102130779A patent/TWI696606B/en not_active IP Right Cessation
- 2013-08-28 AU AU2013307337A patent/AU2013307337B2/en not_active Ceased
- 2013-08-28 UA UAA201502766A patent/UA122385C2/en unknown
- 2013-08-28 TW TW102130781A patent/TWI636036B/en not_active IP Right Cessation
- 2013-08-28 JP JP2015529005A patent/JP6505013B2/en not_active Expired - Fee Related
- 2013-08-28 CR CR20210079A patent/CR20210079A/en unknown
- 2013-08-28 SG SG11201501359TA patent/SG11201501359TA/en unknown
- 2013-08-28 CA CA2880699A patent/CA2880699A1/en not_active Abandoned
- 2013-08-28 SG SG10201605291WA patent/SG10201605291WA/en unknown
- 2013-08-28 CN CN201380044856.2A patent/CN104812743A/en active Pending
- 2013-08-28 CN CN201380045665.8A patent/CN104902885A/en active Pending
- 2013-08-28 JO JOP/2013/0256A patent/JOP20130256B1/en active
- 2013-08-28 NZ NZ74349913A patent/NZ743499A/en not_active IP Right Cessation
- 2013-08-28 NZ NZ704748A patent/NZ704748A/en not_active IP Right Cessation
- 2013-08-28 CN CN202110497671.3A patent/CN113444063A/en active Pending
- 2013-08-28 TW TW107129929A patent/TW201900607A/en unknown
- 2013-08-28 EA EA201590457A patent/EA038942B1/en unknown
- 2013-08-28 CR CR20200276A patent/CR20200276A/en unknown
- 2013-08-28 MX MX2015002697A patent/MX2015002697A/en active IP Right Grant
- 2013-08-28 SG SG10201709133QA patent/SG10201709133QA/en unknown
- 2013-08-28 AP AP2015008249A patent/AP2015008249A0/en unknown
- 2013-08-28 BR BR112015004205-8A patent/BR112015004205B1/en not_active IP Right Cessation
- 2013-08-28 AU AU2013307331A patent/AU2013307331A1/en not_active Abandoned
- 2013-08-28 SG SG11201501362PA patent/SG11201501362PA/en unknown
- 2013-08-28 US US14/423,963 patent/US10676429B2/en active Active
- 2013-08-28 CN CN202110497637.6A patent/CN113321632A/en active Pending
- 2013-08-28 KR KR1020157005871A patent/KR102122244B1/en active IP Right Grant
-
2015
- 2015-01-28 IL IL236967A patent/IL236967A0/en unknown
- 2015-01-29 IL IL23698915A patent/IL236989B/en active IP Right Grant
- 2015-01-30 GT GT201500021A patent/GT201500021A/en unknown
- 2015-01-30 GT GT201500020A patent/GT201500020A/en unknown
- 2015-02-13 PH PH12015500317A patent/PH12015500317A1/en unknown
- 2015-02-23 PH PH12015500387A patent/PH12015500387A1/en unknown
- 2015-02-27 CL CL2015000487A patent/CL2015000487A1/en unknown
- 2015-02-27 NI NI201500029A patent/NI201500029A/en unknown
- 2015-02-27 CL CL2015000488A patent/CL2015000488A1/en unknown
- 2015-02-27 EC ECIEPI20157335A patent/ECSP15007335A/en unknown
- 2015-02-27 NI NI201500030A patent/NI201500030A/en unknown
- 2015-02-27 EC ECIEPI20157322A patent/ECSP15007322A/en unknown
- 2015-09-21 HK HK15109247.5A patent/HK1208465A1/en unknown
- 2015-11-03 HK HK15110806.6A patent/HK1210030A1/en unknown
-
2017
- 2017-06-28 IL IL253225A patent/IL253225B/en active IP Right Grant
- 2017-08-18 US US15/681,309 patent/US10995064B2/en active Active
-
2018
- 2018-06-25 AU AU2018204597A patent/AU2018204597B2/en not_active Ceased
- 2018-09-07 AU AU2018226485A patent/AU2018226485B2/en not_active Ceased
- 2018-11-05 JP JP2018208063A patent/JP6907173B2/en active Active
- 2018-11-05 JP JP2018207904A patent/JP6895938B2/en active Active
-
2019
- 2019-10-16 PH PH12019502355A patent/PH12019502355A1/en unknown
-
2020
- 2020-02-19 AU AU2020201203A patent/AU2020201203A1/en not_active Abandoned
- 2020-04-24 US US16/858,519 patent/US20200255373A1/en not_active Abandoned
- 2020-10-07 US US17/065,463 patent/US20210024462A1/en not_active Abandoned
-
2021
- 2021-06-07 JP JP2021095380A patent/JP2021176846A/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002064618A2 (en) * | 2001-02-09 | 2002-08-22 | Massachusetts Institute Of Technology | Methods of identifying agents that mediate polypeptide aggregation |
US20050239833A1 (en) * | 2004-03-05 | 2005-10-27 | Kazantsev Aleksey G | Compositions and methods for modulating interaction between polypeptides |
US20100016310A1 (en) * | 2006-08-17 | 2010-01-21 | Boehringer Ingelheim International Gmbh | Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors |
US20110009622A1 (en) * | 2008-04-24 | 2011-01-13 | Makoto Jitsuoka | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient |
WO2013006394A1 (en) | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
Non-Patent Citations (8)
Title |
---|
D. CAI ET AL: "Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 56, no. 8, 1 August 2012 (2012-08-01), pages 4277 - 4288, XP055059505, ISSN: 0066-4804, DOI: 10.1128/AAC.00473-12 * |
LAMBENG ET AL: "Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: Identification of a lead and initial SAR studies", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, vol. 17, no. 1, 22 December 2006 (2006-12-22), pages 272 - 277, XP005812156, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2006.09.049 * |
MAI S MABROUK: "Discovering best candidates for Hepatocellular Carcinoma (HCC) by in-silico techniques and tools", INT. J. BIOINFORMATICS RESEARCH AND APPLICATIONS, vol. 8, no. 1/2, 1 January 2012 (2012-01-01), pages 141 - 152, XP055059465 * |
NAM DOO KIM ET AL: "Discovery of novel HCV polymerase inhibitors using pharmacophore-based virtual screening", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, GB, vol. 21, no. 11, 4 April 2011 (2011-04-04), pages 3329 - 3334, XP028211474, ISSN: 0960-894X, [retrieved on 20110409], DOI: 10.1016/J.BMCL.2011.04.010 * |
ORGANIC PROCESS RESEARCH & DEVELOPMENT, vol. 13, no. 5, 2009, pages 875 - 879 |
PHOSPHORUS, SULFUR, AND SILICON AND THE RELATED ELEMENTS, vol. 56, 1991, pages 1 - 4 |
WEBER ET AL., ANTIVIRAL RES., vol. 54, pages 69 - 78 |
ZHANG XIAOQIAN ET AL: "A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 102, no. 3, 18 January 2005 (2005-01-18), pages 892 - 897, XP009116402, ISSN: 0027-8424, DOI: 10.1073/PNAS.0408936102 * |
Cited By (185)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10196376B2 (en) | 2011-12-21 | 2019-02-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9676747B2 (en) | 2011-12-21 | 2017-06-13 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9061008B2 (en) | 2011-12-21 | 2015-06-23 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9066932B2 (en) | 2011-12-21 | 2015-06-30 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9751857B2 (en) | 2011-12-21 | 2017-09-05 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US10676429B2 (en) | 2012-08-28 | 2020-06-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10995064B2 (en) | 2012-08-28 | 2021-05-04 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US9938236B2 (en) | 2012-12-27 | 2018-04-10 | Drexel University | Antiviral agents against HBV infection |
US10941113B2 (en) | 2013-02-28 | 2021-03-09 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
US10125094B2 (en) | 2013-02-28 | 2018-11-13 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B |
AU2014222641B2 (en) * | 2013-02-28 | 2018-03-15 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
US9205079B2 (en) | 2013-03-12 | 2015-12-08 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9579313B2 (en) | 2013-03-12 | 2017-02-28 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
US9895349B2 (en) | 2013-04-03 | 2018-02-20 | Janssen Sciences Ireland Us | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10398677B2 (en) | 2013-04-03 | 2019-09-03 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR20160008574A (en) * | 2013-05-17 | 2016-01-22 | 얀센 사이언시즈 아일랜드 유씨 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
EP3594204A1 (en) | 2013-05-17 | 2020-01-15 | Janssen Sciences Ireland Unlimited Company | Preparation of sulphamoylpyrrolamide derivatives for the treatment of hepatitis b |
EP3121164A1 (en) | 2013-05-17 | 2017-01-25 | Janssen Sciences Ireland UC | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR102223535B1 (en) | 2013-05-17 | 2021-03-08 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR20190139328A (en) * | 2013-05-17 | 2019-12-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
KR102055639B1 (en) | 2013-05-17 | 2019-12-13 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10457638B2 (en) | 2013-05-17 | 2019-10-29 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10160743B2 (en) | 2013-05-17 | 2018-12-25 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR20180066279A (en) * | 2013-05-17 | 2018-06-18 | 얀센 사이언시즈 아일랜드 유씨 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9884818B2 (en) | 2013-05-17 | 2018-02-06 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
KR101867898B1 (en) * | 2013-05-17 | 2018-06-15 | 얀센 사이언시즈 아일랜드 유씨 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2014184365A1 (en) | 2013-05-17 | 2014-11-20 | Janssen R&D Ireland | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10071961B2 (en) | 2013-10-23 | 2018-09-11 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US10377709B2 (en) | 2013-10-23 | 2019-08-13 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
US9873671B2 (en) | 2014-01-16 | 2018-01-23 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9505722B2 (en) | 2014-01-16 | 2016-11-29 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9339510B2 (en) | 2014-01-16 | 2016-05-17 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US10213420B2 (en) | 2014-02-05 | 2019-02-26 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US10632112B2 (en) | 2014-02-05 | 2020-04-28 | Novira Therapeutics, Inc. | Combination therapy for treatment of HBV infections |
US11078193B2 (en) | 2014-02-06 | 2021-08-03 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3607950A2 (en) | 2014-03-13 | 2020-02-12 | Indiana University Research & Technology Corporation | Hepatitis b core protein allosteric modulators |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
US10428041B2 (en) | 2014-12-30 | 2019-10-01 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
US10160742B2 (en) | 2014-12-30 | 2018-12-25 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
US20160185748A1 (en) * | 2014-12-30 | 2016-06-30 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for hbv treatment |
US9765050B2 (en) * | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
US11168086B2 (en) | 2015-01-16 | 2021-11-09 | Hoffmann-La Roche Inc. | Methods of synthesizing pyrazine compounds |
US9890167B2 (en) | 2015-01-16 | 2018-02-13 | Hoffmann-La Roche Inc. | Pyrazine compounds for the treatment of infectious diseases |
WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
EP3321265A1 (en) | 2015-03-04 | 2018-05-16 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine compounds and their utilisation as modulators of toll-like receptors |
EP3722297A1 (en) | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
WO2016149581A1 (en) * | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
JP2018510159A (en) * | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | Azocan and azonan derivatives and methods for treating hepatitis B infection |
US9884831B2 (en) | 2015-03-19 | 2018-02-06 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
CN107847762A (en) * | 2015-03-19 | 2018-03-27 | 诺维拉治疗公司 | Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection |
US10537580B2 (en) | 2015-03-19 | 2020-01-21 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis B infections |
US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
EP3590943A1 (en) | 2015-07-02 | 2020-01-08 | Janssen Sciences Ireland Unlimited Company | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
WO2017035230A1 (en) | 2015-08-26 | 2017-03-02 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
WO2017048962A1 (en) | 2015-09-15 | 2017-03-23 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
EP3782626A1 (en) | 2015-09-15 | 2021-02-24 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
WO2017048954A1 (en) | 2015-09-15 | 2017-03-23 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
US10934306B2 (en) | 2016-03-07 | 2021-03-02 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
US10441589B2 (en) | 2016-04-15 | 2019-10-15 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US11129834B2 (en) | 2016-04-15 | 2021-09-28 | Novira Therapeutics, Inc. | Combinations and methods comprising a capsid assembly inhibitor |
US10604527B2 (en) | 2016-05-20 | 2020-03-31 | Hoffmann-La Roche Inc. | Pyrazine compounds for the treatment of hepatitis B infection |
WO2017205115A1 (en) | 2016-05-27 | 2017-11-30 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
WO2017205078A1 (en) | 2016-05-27 | 2017-11-30 | Gilead Sciences, Inc. | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
US10562905B2 (en) | 2016-07-14 | 2020-02-18 | Hoffmann-La Roche Inc. | Carboxy tetrahydropyrazolopyrazine compounds for the treatment of infectious diseases |
US10683299B2 (en) | 2016-07-14 | 2020-06-16 | Hoffmann La Roche Inc. | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases |
US10781206B2 (en) | 2016-07-14 | 2020-09-22 | Hoffmann La-Roche Inc. | Tetrahydropyrazolopyridine compounds for the treatment of infectious diseases |
WO2018039531A1 (en) | 2016-08-26 | 2018-03-01 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10874640B2 (en) | 2016-08-26 | 2020-12-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US10328053B2 (en) | 2016-08-26 | 2019-06-25 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
EP3922634A1 (en) | 2016-08-26 | 2021-12-15 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
WO2018053157A1 (en) | 2016-09-15 | 2018-03-22 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
US11274285B2 (en) | 2016-10-14 | 2022-03-15 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome |
WO2018085619A1 (en) | 2016-11-07 | 2018-05-11 | Arbutus Biopharma, Inc. | Substituted pyridinone-containing tricyclic compounds, and methods using same |
WO2018144390A1 (en) | 2017-01-31 | 2018-08-09 | Gilead Sciences, Inc. | Crystalline forms of tenofovir alafenamide |
WO2018144605A1 (en) | 2017-02-02 | 2018-08-09 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
US10442804B2 (en) | 2017-02-02 | 2019-10-15 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis B virus infection |
WO2018160090A1 (en) | 2017-02-28 | 2018-09-07 | Александр Васильевич ИВАЩЕНКО | Antiviral composition and method for using same |
WO2018160878A1 (en) | 2017-03-02 | 2018-09-07 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
WO2018172852A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
WO2018195321A1 (en) | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
EP4026835A2 (en) | 2017-04-20 | 2022-07-13 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
RU2666727C1 (en) * | 2017-07-18 | 2018-09-12 | Андрей Александрович Иващенко | Hepatitis b (hbv) inhibitor |
WO2019017814A1 (en) * | 2017-07-18 | 2019-01-24 | Александр Васильевич ИВАЩЕНКО | Hepatitis b virus (hbv) inhibitor |
WO2019040102A1 (en) | 2017-08-22 | 2019-02-28 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
US11596611B2 (en) | 2017-08-28 | 2023-03-07 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
WO2019086141A1 (en) | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2019086142A1 (en) | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019165374A1 (en) | 2018-02-26 | 2019-08-29 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
US11420974B2 (en) | 2018-02-26 | 2022-08-23 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
WO2019166532A1 (en) | 2018-03-01 | 2019-09-06 | Janssen Sciences Ireland Unlimited Company | 2,4-diaminoquinazoline derivatives and medical uses thereof |
EP4059924A1 (en) | 2018-03-01 | 2022-09-21 | Janssen Sciences Ireland Unlimited Company | 2,4-diaminoquinazoline derivatives and medical uses thereof |
US11597704B2 (en) | 2018-03-01 | 2023-03-07 | Janssen Sciences Ireland Unlimited Company | 2,4-diaminoquinazoline derivatives and medical uses thereof |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
US11149052B2 (en) | 2018-04-06 | 2021-10-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′-cyclic dinucleotides |
WO2019193543A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides |
WO2019193542A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides |
WO2019193533A1 (en) | 2018-04-06 | 2019-10-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2'-cyclic dinucleotides |
US11292812B2 (en) | 2018-04-06 | 2022-04-05 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotides |
WO2019200247A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
US11788077B2 (en) | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
US11098027B2 (en) | 2018-07-06 | 2021-08-24 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2020010200A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
WO2020010223A1 (en) | 2018-07-06 | 2020-01-09 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
EP4234030A2 (en) | 2018-07-13 | 2023-08-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020014643A1 (en) | 2018-07-13 | 2020-01-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
US11377450B2 (en) | 2018-09-21 | 2022-07-05 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2020072955A1 (en) * | 2018-10-05 | 2020-04-09 | Emory University | Monomer and multimeric anti-hbv agents |
US11560370B1 (en) | 2018-10-22 | 2023-01-24 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of HBV |
WO2020086533A1 (en) | 2018-10-22 | 2020-04-30 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
WO2020092621A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
WO2020087107A1 (en) | 2018-10-31 | 2020-05-07 | The University Of Sydney | Compositions and methods for treating viral infections |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
WO2020089453A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020089459A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv) |
WO2020089452A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-pyrazolo[4,3-c]pyridines active against the hepatitis b virus (hbv) |
WO2020089460A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv) |
WO2020089455A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020089456A1 (en) | 2018-11-02 | 2020-05-07 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazines active against the hepatitis b virus (hbv) |
US11891393B2 (en) | 2018-11-21 | 2024-02-06 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2020123674A1 (en) | 2018-12-12 | 2020-06-18 | Arbutus Biopharma Corporation | Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same |
US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
WO2020214663A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020214652A1 (en) | 2019-04-17 | 2020-10-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
WO2020221826A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
WO2020221811A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis b virus (hbv) |
WO2020221816A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel phenyl and pyridyl ureas active against the hepatitis b virus (hbv) |
WO2020221824A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
US11491148B2 (en) | 2019-05-06 | 2022-11-08 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020242999A1 (en) | 2019-05-24 | 2020-12-03 | Assembly Biosciences, Inc. | Pharmaceutical compositions for the treatment of hbv |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
EP4028394A4 (en) * | 2019-09-04 | 2023-10-11 | Taigen Biotechnology Co., Ltd. | Hepatitis b antiviral agents |
US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
WO2021216642A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2021216661A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | Pyrazole carboxamide compounds for treatment of hbv |
WO2021216660A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2021216656A1 (en) | 2020-04-22 | 2021-10-28 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2022031894A1 (en) | 2020-08-07 | 2022-02-10 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
WO2022087149A2 (en) | 2020-10-22 | 2022-04-28 | Gilead Sciences, Inc. | Interleukin-2-fc fusion proteins and methods of use |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023069544A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069547A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023069545A1 (en) | 2021-10-20 | 2023-04-27 | Assembly Biosciences, Inc. | 5-membered heteroaryl carboxamide compounds for treatment of hbv |
WO2023164181A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164186A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164179A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
WO2023164183A1 (en) | 2022-02-25 | 2023-08-31 | Assembly Biosciences, Inc. | Benzothia(dia)zepine compounds for treatment of hbv and hdv |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018204597B2 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B | |
EP2961732A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
OA17199A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. | |
OA17200A (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13756110 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 236967 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2880699 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: NC2017/0011318 Country of ref document: CO Ref document number: 15018702 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2015-000060 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015500317 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2013307331 Country of ref document: AU Date of ref document: 20130828 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14423963 Country of ref document: US Ref document number: IDP00201501115 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2015529005 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/002696 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20157005867 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013756110 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201590457 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015004192 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015004192 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150226 |